KING PHARMACEUTICALS, INC. - FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 2007 (March 21, 2007)
King Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Tennessee
|
|
001-15875
|
|
54-1684963 |
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.) |
|
|
|
501 Fifth Street, Bristol, Tennessee
|
|
37620 |
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (423) 989-8000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions ( see General
Instruction A.2. below):
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
|
|
|
Item 5.02. |
|
Departure of Directors or Principal Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 21, 2007, the Compensation and Human Resources Committee (the Committee) of the
Board of Directors (the Board) of King Pharmaceuticals, Inc. (King) approved the 2007 Executive
Management Incentive Award (the 2007 EMIA), which contains the parameters under which certain
executives of King will be eligible to receive cash incentive awards for performance during the
2007 fiscal year.
Under the 2007 EMIA, adopted pursuant to the King Pharmaceuticals, Inc. Incentive Plan, awards
to executive officers (as defined by the Securities Exchange Act of 1934 and referred to in this
document as Executive Officers) and other executives who report to the Chief Executive Officer
will be based upon accomplishment of one or two financial objectives (Financial Objectives).
Awards to other EMIA Participants (as defined below) will be based upon accomplishment of Financial
Objectives and approximately four individual operational objectives (Operational Objectives).
Executives having the title of Vice President or a more senior title as of March 21, 2007 are
eligible to participate in the 2007 EMIA, including all Executive Officers (each such person being
an EMIA Participant). The Committee may establish an EMIA for other persons who become Executive
Officers after March 21, 2007, and the Chief Executive Officer may establish an EMIA for other
persons who become EMIA Participants after March 21, 2007, in each case with certain limitations as
described in the 2007 EMIA.
Under the terms of the 2007 EMIA, the Committee has established and approved all Financial
Objectives and must approve any amendments to those objectives. The Committee has also approved the
specific weighting of the Financial Objectives for the Executive Officers and must approve any
amendments thereto. Potential EMIA awards for Executive Officers are based upon prospective
financial goals, the accomplishment of which was substantially uncertain at the time of their
establishment. For EMIA Participants who are not Executive Officers, the Chief Executive Officer or
his designee must approve (1) the weighting of their Financial Objectives, based upon each EMIA
Participants ability to impact the accomplishment of those objectives, and (2) their Operational
Objectives, and any amendments to either of these items.
Payment of any 2007 EMIA award is contingent upon the Committees determination that the
applicable Financial Objectives have been met, and at what achievement level those objectives have
been met. In addition, payment of any 2007 EMIA award shall be contingent upon either the
Committees or the Chief Executive Officers (or his designees) determination, as appropriate,
that the EMIA Participant has satisfied the applicable achievement level with respect to his or her
Operational Objectives.
In order to receive a 2007 EMIA award, the EMIA Participant must continue to be employed by
King on December 31, 2007, except in the case of death, disability or approved retirement.
The Committee, in its discretion, may reduce or eliminate any EMIA award if it determines such
action to be in the best interests of King. The Committee may also, at any time, amend or terminate
the 2007 EMIA program.
On March 21, 2007, the Committee also approved a merit salary increase for Brian A. Markison,
Kings President and Chief Executive Officer, effective immediately, in recognition of his
contributions to King since August 2005, the time of Mr. Markisons most recent base salary
adjustment. Mr. Markisons salary was increased to $950,000, an increase of $125,000.
On March 21, 2007, the Committee also approved the following revised form documents to be used
pursuant to the Companys Incentive Plan: Form of Option Certificate and Nonstatutory Stock Option
Agreement; Form of Restricted Stock Certificate and Restricted Stock Grant Agreement; Form of
Long-Term Performance Unit Award Agreement One Year Performance Cycle; and Form of Long-Term
Performance Unit Award Agreement Three Year
Performance Cycle, all attached hereto as exhibits. The forms were revised to eliminate the
requirement for a manual signature by the grant recipient.
|
|
|
Item 9.01 |
|
Financial Statements and Exhibits. |
(d) Exhibits
|
10.1 |
|
Form of Option Certificate and Nonstatutory Stock Option Agreement |
|
|
10.2 |
|
Form of Restricted Stock Certificate and Restricted Stock Grant Agreement |
|
|
10.3 |
|
Form of Long-Term Performance Unit Award Agreement One Year Performance Cycle |
|
|
10.4 |
|
Form of Long-Term Performance Unit Award Agreement Three Year Performance Cycle |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: March 27, 2007 |
KING PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ Joseph Squicciarino
|
|
|
|
Joseph Squicciarino
Chief Financial Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
No. |
|
Description |
10.1
|
|
Form of Option Certificate and
Nonstatutory Stock Option Agreement |
|
|
|
10.2
|
|
Form of Restricted Stock
Certificate and Restricted Stock
Grant Agreement |
|
|
|
10.3
|
|
Form of Long-Term Performance Unit
Award Agreement One Year
Performance
Cycle |
|
|
|
10.4
|
|
Form of Long-Term Performance Unit
Award Agreement Three Year
Performance
Cycle |